Researchers at Sanford Burnham Prebys, led by Ze’ev Ronai, Ph.D., have shown for the first time that inhibiting a key metabolic enzyme selectively kills melanoma cells and stops tumor growth. Published in Nature Cell Biology, these findings could lead to a new class of drugs to selectively treat melanoma, the most severe form of skin cancer.
2022
SkylineDx Gains CE-IVD Mark for Melanoma Metastasis Risk Assay
NEW YORK — SkylineDx said on Thursday that it has obtained CE-IVD marking for its Merlin Assay to predict which melanoma patients are at low risk of nodal metastasis.
Addition of T-VEC to Pembrolizumab in Advanced Melanoma
As reported in the Journal of Clinical Oncology by Chesney et al, the phase III MASTERKEY-265 trial has shown no significant improvement in progression-free survival or overall survival with the addition of talimogene laherparepvec (T-VEC) to pembrolizumab in patients with advanced melanoma.
Strongest evidence yet shows negligible increase in melanoma risk from methotrexate
A new meta-analysis from School of Public Health and Preventive Medicine researchers shows that the widely-used anti-inflammatory methotrexate has a negligible effect on the risk of developing melanoma, essentially a 0.005 per cent risk increase for Australians using the drug. The findings allay growing concerns among the medical community around this potential side effect.